Yüklüyor......
Prevention of Bone Loss with Risedronate in Breast Cancer Survivors: A Randomized, Controlled Clinical Trial
PURPOSE: Aromatase inhibitors (AIs), adjuvant endocrine therapy for postmenopausal women with hormone receptor positive breast cancer, are associated with bone loss and fractures. Our objectives were to determine if 1) oral bisphosphonate therapy can prevent bone loss in women on an AI and, 2) early...
Kaydedildi:
Yayımlandı: | Osteoporos Int |
---|---|
Asıl Yazarlar: | , , , , , , , , |
Materyal Türü: | Artigo |
Dil: | Inglês |
Baskı/Yayın Bilgisi: |
2015
|
Konular: | |
Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4766869/ https://ncbi.nlm.nih.gov/pubmed/25792492 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s00198-015-3100-7 |
Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|